Lyell Immunopharma Return on Equity

Lyell Immunopharma (LYEL) currently reports a ROE of -106.27%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore Lyell Immunopharma's ROE history and peer comparisons.

Lyell Immunopharma's ROE of -106.27% is lower than the Healthcare sector average of -100.59%. That is roughly 5.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Lyell Immunopharma's current -106.27% should be judged against Healthcare norms (sector average: -100.59%) and against LYEL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -106.27%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Lyell Immunopharma, and consider following LYEL for alerts when major investors trade the stock.

Lyell Immunopharma is classified in the Healthcare sector. On ROE, it currently shows -106.27% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LYEL with unrelated industries.